Welcome to our dedicated page for Clearside Biomed news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomed stock.
This page contains historical news coverage for Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company that specialized in suprachoroidal drug delivery technology for retinal diseases. In late 2025, Clearside announced its decision to pursue a strategic sale through voluntary Chapter 11 bankruptcy proceedings. This news archive documents the company's journey, including its clinical development programs, regulatory milestones, and the events leading to its bankruptcy filing.
Clearside's news history reflects the challenges and milestones typical of clinical-stage ophthalmology companies. Coverage includes updates on XIPERE, the company's FDA-approved treatment for uveitic macular edema, as well as clinical trial progress for CLS-AX, their pipeline candidate for wet age-related macular degeneration. The archive also documents partnership announcements with companies like Arctic Vision and regulatory approvals in international markets.
For investors researching the ophthalmic drug delivery sector or studying the trajectory of clinical-stage biopharmaceutical companies, this historical news collection provides insight into Clearside's business development, financing activities, and strategic decisions. The coverage spans product commercialization efforts, scientific presentations at ophthalmology conferences, and ultimately the announcement of strategic alternatives exploration that preceded the Chapter 11 filing.
Browse this archive to understand the sequence of events in Clearside Biomedical's corporate history and the factors that shaped its path from innovative suprachoroidal platform developer to bankruptcy proceedings.
Clearside Biomedical, Inc. (Nasdaq: CLSD) reported Q1 2024 financial results, focusing on the Phase 2b ODYSSEY Trial in Wet AMD with data expected in Q3 2024. The company aims to revolutionize eye therapy delivery through the suprachoroidal space. Management team strengthened with key additions like new Chief Medical Officer and Board member. Revenue increased, highlighting the successful completion of a direct offering, and positive data presentations on suprachoroidal drug delivery.
Clearside Biomedical, Inc., a biopharmaceutical company specializing in delivering therapies to the back of the eye, will have its CEO and CMO participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on May 14, 2024. The webcast can be accessed on the company's website.
Clearside Biomedical, Inc., will report its first quarter 2024 financial results on May 9, 2024, after the market closes. The company will also provide a corporate update during a webcast and conference call. Investors can access the live and archived webcast on the Clearside website and join the call by dialing the provided numbers.
FAQ
What is the current stock price of Clearside Biomed (CLSD)?
What is the market cap of Clearside Biomed (CLSD)?
